A. Mochizuki et al. / Bioorg. Med. Chem. Lett. 21 (2011) 7337–7343
7343
dependent inhibition.17 We expect that our zwitter ionic fXa inhib-
itors would have superior profiles that other basic and neutral fXa
inhibitors didn’t have.
8221; (n) Yoshikawa, K.; Yoshino, T.; Yokomizo, Y.; Naito, H.; Kawakami, K.;
Mochizuki, A.; Nagata, T.; Suzuki, M.; Kanno, H.; Takemura, M.; Ohta, T. Bioorg.
Med. Chem. Lett. 2011, 21, 2133.
4. Mochizuki, A.; Nagata, T.; Kanno, H.; Suzuki, M.; Ohta, T. Bioorg. Med. Chem.
2011, 19, 1623.
5. Furugohri, T.; Isobe, K.; Honda, Y.; Kamisato-Matsumoto, C.; Sugiyama, N.;
Nagahara, T.; Morishima, Y.; Shibano, T. J. Thromb. Haemost. 2008, 6, 1542.
6. Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer, J.; Schlemmer, K.
H.; Reinemer, P.; Perzborn, E. J. Med. Chem. 2005, 48, 5900.
7. Pinto, D. J. P.; Orwat, M. J.; Koch, S.; Rossi, K. A.; Alexander, R. S.; Smallwood, A.;
Wong, P. C.; Rendina, A. R.; Luettgen, J. M.; Knabb, R. M.; He, K.; Xin, B.; Wexler,
R. R.; Lam, P. Y. S. J. Med. Chem. 2007, 50, 5339.
Acknowledgment
We are grateful to the anticoagulant group in Biological Re-
search Laboratory for performing the biological assays.
References and notes
8. Predicted pKa value was calculated by Pallas program.
9. (a) Dansette, P. M.; Bertho, G.; Mansuy, D. Biochem. Biophys. Res. Commun. 2005,
338, 450; (b) Medower, C.; Wen, L.; Johnson, W. W. Chem. Res. Toxicol. 2008, 21,
1570.
1. (a) Prager, N. A.; Abendschein, D. R.; McKenzie, C. R.; Eisenberg, P. R. Circulation
1995, 92, 962; (b) Kunitada, S.; Nagahara, T. Curr. Pharm. Des. 1996, 2, 531.
2. There are so many reports. Almost all reports about the fXa inhibitor were cited
in recent reviews. (a) Pinto, D. J. P.; Smallheer, J. M.; Cheney, D. L.; Knabb, R. M.;
Wexler, R. R. J. Med. Chem. 2010, 53, 6243; (b) Straub, A.; Roehrig, S.; Hillisch, A.
Angew. Chem., Int. Ed. 2011, 50, 4574.
10. The X-ray crystal structure coordinates of ligands in fXa have been deposited in
the Protein Data Bank (compound 20B: 3TK5, compound 1: 3TK6).
11. S1-b pocket (also known as ‘ester binding pocket’) is composed of Gln192,
Arg143, Glu147, and Cys191-Cys220 disulfide bridge. Several inhibitors were
reported to interact with this hydrophobic pocket similar to our previous
report 4n. (a) Nazaré, M.; Will, D. W.; Matter, H.; Schreuder, H.; Ritter, K.;
Urmann, M.; Essrich, M.; Bauer, A.; Wagner, M.; Czech, J.; Lorenz, M.; Laux, V.;
Wehner, V. J. Med. Chem. 2005, 48, 4511; (b) Adler, M.; Kochanny, M. J.; Ye, B.;
Rumennik, G.; Light, D. R.; Biancalana, S.; Whitlow, M. Biochemistry 2002, 41,
15514; (c) Qiao, J. X.; Wang, T. C.; Wang, G. Z.; Cheney, D. L.; He, K.; Rendina, A.
R.; Xin, B.; Luettgen, J. M.; Knabb, R. M.; Wexler, R. R.; Lam, P. Y. S. Bioorg. Med.
Chem. Lett. 2007, 17, 5041; (d) Anselm, L.; Banner, D. W.; Benz, J.; Zbinden, K.
G.; Himber, J.; Hilpert, H.; Huber, W.; Kuhn, B.; Mary, J.-L.; Otteneder, M.;
Panday, N.; Ricklin, F.; Stahl, M.; Tohmi, S.; Haap, W. Bioorg. Med. Chem. Lett.
2010, 20, 5313.
12. Iv administration tests was examained at 1 mg/kg to two monkeys as HCl salts.
Serum concentration were measured at 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 h after
iv administration. The measuring methods were described in Ref. 4.
13. Haginoya, N.; Komoriya, S.; Osanai, K.; Yoshino, T.; Nagata, T.; Nagamochi, M.;
Muto, R.; Yamaguchi, M.; Nagahara, T.; Kanno, H. Heterocycles 2004, 63, 1555.
14. Duncia, J. V.; Pierce, M. E.; Santella, J. B., III J. Org. Chem. 1991, 56, 2395.
15. Vetelino, M. G.; Coe, J. W. Tetrahedron Lett. 1994, 35, 219.
3. (a) Haginoya, N.; Kobayashi, S.; Komoriya, S.; Yoshino, T.; Suzuki, M.; Shimada,
T.; Watanabe, K.; Hirokawa, Y.; Furugoori, T.; Nagahara, T. J. Med. Chem. 2004,
47, 5167; (b) Haginoya, N.; Kobayashi, S.; Komoriya, S.; Hirokawa, Y.;
Furugoori, T.; Nagahara, T. Bioorg. Med. Chem. Lett. 2004, 14, 2935; (c)
Haginoya, N.; Kobayashi, S.; Komoriya, S.; Yoshino, T.; Nagata, T.; Hirokawa,
Y.; Nagahara, T. Bioorg. Med. Chem. 2004, 12, 5579; (d) Komoriya, S.; Kanaya, N.;
Nagahara, T.; Yokoyama, A.; Inamura, K.; Yokoyama, Y.; Katakura, S.; Hara, T.
Bioorg. Med. Chem. 2004, 12, 2099; (e) Komoriya, S.; Haginoya, N.; Nagata, T.;
Suzuki, M.; Kobayashi, S.; Mochizuki, A.; Yoshino, T.; Nagahara, T.; Suzuki, M.;
Isobe, Y.; Furugoori, T. Bioorg. Med. Chem. 2005, 13, 3927; (f) Komoriya, S.;
Kobayashi, S.; Osanai, K.; Yoshino, T.; Nagata, T.; Haginoya, N.; Nakamoto, Y.;
Mochizuki, A.; Nagahara, T.; Suzuki, M.; Shimada, T.; Watanabe, K.; Isobe, Y.;
Furugoori, T. Bioorg. Med. Chem. 2006, 14, 1309; (g) Nagata, T.; Yoshino, T.;
Haginoya, N.; Yoshikawa, K.; Nagamochi, M.; Kobayashi, S.; Komoriya, S.;
Yokomizo, A.; Muto, R.; Yamaguchi, M.; Osanai, K.; Suzuki, M.; Kanno, H. Bioorg.
Med. Chem. 2009, 17, 1193; (h) Nagata, T.; Yoshino, T.; Haginoya, N.;
Yoshikawa, K.; Isobe, Y.; Furugohri, T.; Kanno, H. Bioorg. Med. Chem. Lett.
2007, 17, 4683; (i) Nagata, T.; Nagamochi, M.; Kobayashi, S.; Komoriya, S.;
Yoshino, T.; Kanno, H. Bioorg. Med. Chem. Lett. 2008, 18, 4587; (j) Mochizuki, A.;
Nakamoto, Y.; Naito, H.; Uoto, K.; Ohta, T. Bioorg. Med. Chem. Lett. 2008, 18, 782;
(k) Mochizuki, Y.; Naito, H.; Nakamoto, A.; Uoto, K.; Ohta, T. Heterocycles 2008,
75, 1659; (l) Yoshikawa, K.; Yokomizo, A.; Naito, H.; Haginoya, N.; Kobayashi,
S.; Yoshino, T.; Nagata, T.; Mochizuki, A.; Osanai, K.; Watanabe, K.; Kano, H.;
Ohta, T. Bioorg. Med. Chem. 2009, 17, 8206; (m) Yoshikawa, K.; Kobayashi, S.;
Nakamoto, Y.; Haginoya, N.; Komoriya, S.; Yoshino, T.; Nagata, T.; Mochizuki,
A.; Watanabe, K.; Suzuki, M.; Kano, H.; Ohta, T. Bioorg. Med. Chem. 2009, 17,
16. Zhu, B.; Jia, Z.; Zhang, P.; Su, T.; Huang, W.; Goldman, E.; Tumas, D.; Kadambi,
V.; Eddy, P.; Sinha, U.; Scarborough, R. M.; Song, Y. Bioorg. Med. Chem. Lett.
2006, 16, 5507.
17. Aspiotis, R.; Chen, A.; Cauchon, E.; Dube, D.; Falgueyret, J.-P.; Gagne, S.; Gallant,
M.; Grimm, E. L.; Houle, R.; Juteau, H.; Lacombe, P.; Laliberte, S.; Levesque, J.-F.;
MacDonald, D.; McKay, D.; Percival, M. D.; Roy, P.; Soisson, S. M.; Wu, T. Bioorg.
Med. Chem. Lett. 2011, 21, 2430.